prevacid capsule 30 mg
takeda pharmaceuticals (asia pacific) pte. ltd. - lansoprazole - capsule - 30 mg - lansoprazole 30 mg
immunate 50 iuml powder and solvent for solution for injection
takeda malaysia sdn bhd - von willebrand factor; human blood coagulation factor viii -
immunate 100 iuml powder and solvent for solution for injection
takeda malaysia sdn bhd - von willebrand factor; human blood coagulation factor viii -
vocinti 20mg film-coated tablet
takeda malaysia sdn bhd - vonoprazan fumarate -
vocinti 10mg film-coated tablet
takeda malaysia sdn bhd - vonoprazan fumarate -
entyvio i.v.
takeda israel ltd - vedolizumab - powder for concentrate for solution for infusion - vedolizumab 300 mg/vial - vedolizumab - ulcerative colitis:entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.crohn’s disease:entyvio is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (tnfα) antagonist.
hyqvia
takeda israel ltd - human normal immunoglobulin - solution for infusion - human normal immunoglobulin 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - replacement therapy in adults, children and adolescents (0-18 years) in:• primary immunodeficiency syndromes with impaired antibody production • hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (cll), in whom prophylactic antibiotics have failed or are contra-indicated.• hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (mm) patients.• hypogammaglobulinaemia in patients pre- and post-allogeneic hematopoietic stem cell transplantation (hsct).
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro 3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.